



#17
PATENT 7/31/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Markus Moser, Bruno Oesch and Carsten Korth

Serial No.: 09/508,828

Art Unit: 1632

Filed: July 24, 2000

Title: SYNTHETIC POLYPEPTIDE FOR DIAGNOSING AND TREATING
PRION-RELATED DISEASES

Examiner: Anne-Marie Baker

Docket No.: SCH-32409

SUBSTITUTE SEQUENCE LISTING UNDER §1.825
RESPONSE TO OFFICE ACTION
(In response to Paper No. 14)

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

USPTO
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

The present communication is filed in response to the Office action dated May 29, 2002. The 30 day period for responding to the Office action expired on June 28, 2002. Accordingly, applicant hereby requests and petitions that the time period for responding to the Office action be extended, for one month, to July 28, 2002. A check for the \$55.00 small entity one month extension of time fee is enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: USPTO, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date indicated below.


Signature of Person Mailing Paper

7/19/2002
Date

David E. Spaw
Printed Name of Person Mailing Paper

In response to the Notice included with Paper No. 14, enclosed herewith is a substitute sequence listing in compliance with 37 CFR Sections 1.821-1.825. The substitute sequence listing is being submitted as substitute sheets and is meant to replace the sequence listing of record in this case, according to 1.825(a). In accordance with 1.825(b), a substitute copy of the computer readable form of the sequence listing is also enclosed. The undersigned hereby certifies that the substitute sequence listing includes no new matter, and that the computer readable form is identical to the paper form of the sequence listing. If required, the Office is hereby instructed to enter the paper copy of the sequence listing into the specification.

The Examiner is invited to initiate a telephone interview with the undersigned attorney to expedite prosecution of the present application. If there are any additional fees resulting from this communication, please charge same to our Deposit Account No. 18-0160, our Order No. SCH-32409.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK LLP

By


David E. Spaw, Reg. No. 34732

700 Huntington Building
925 Euclid Avenue
Cleveland, Ohio 44115-1405
(216) 566-9700
Customer No. 007609

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ A **substitute** computer readable form (CRF) copy of the "Sequence Listing".
- ☒ A **substitute** paper copy of the "Sequence Listing", **as well as an amendment directing its entry into the specification.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900